Jubilant Biosys has achieved an early-stage milestone in their collaborative partnership with Sanofi focused on metabolic disorders. The milestone reflects the successful transition of a program to the next phase in the discovery and development process.

The alliance started in 2016 and focuses on the discovery and development of small molecule inhibitors for multiple targets designed to address the unmet medical needs in diabetes and obesity. Jubilant Biosys will continue to apply its integrated drug discovery platform to generate novel molecules that can demonstrate clinical proof-of-mechanism.

“Since inception of this collaboration, the teams at Jubilant Biosys and Sanofi have worked closely on several first-in-class metabolic disease programs. We look forward to advancing these programs further through the discovery and development process to deliver important new therapeutics to treat diabetes,” said Mr. Steven Hutchins, president of Drug Discovery Solutions at Jubilant Biosys.